Alderley Park Ventures
VC Fund
Nottingham, United Kingdom
Alderley Park Ventures is a £5M seed investment fund managed by BioCity following a significant contribution by AstraZeneca.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Alderley Park Ventures invests in
Stages Alderley Park Ventures invests in
Countries Alderley Park Ventures invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Biopharma 2 (50%)
- Health Care 2 (50%)
- Pharmaceutical 2 (50%)
- Medical 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
- Venture - Series Unknown 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Maxwellia
|
Maxwellia is a pioneering ‘prescription to over the counter’ medicines company which specialises in ‘switching’ - the conversion of prescription medicines into branded versions that can be bought without a prescription, over the counter (OTC). | $4.4M / Venture - Series Unknown / Apr 08, 2021 | |
Kinomica
|
Kinomica is a proteomic-data science and diagnostics company specializing in cell signalling. Kinomica offers KScanTM, a powerful suite of advanced proprietary bioinformatics and phosphoproteomics analytical methods that can provide direct activity measurements of multiple endogenous kinases and comprehensive cell signalling network coverage. | $5.1M / Series A / Dec 14, 2020 | |
BiVictriX Therapeutics
|
BiVictriX is a drug discovery and development company. Their services include oncology, haematological malignancies, bispecific ADC therapeutics, biotherapeutics, immunotherapy, antibody research, and drug development. | Seed / Aug 19, 2019 | |
metaLinear
|
metaLinear focuses on the identification and validation of new drug targets for difficult to treat bacterial infections.metaLinear uses a proprietary proteome engineering platform technology to uncover, characterise and validate new targets for antibiotics. Using very large libraries of Randomised proteins (R-teins) expressed in target bacteria,metaLinear will screen for novel targets responsible for the desired phenotype. A key advantage of this approach is the ability to de-risk targets and hence provide multiple efficiency gains in the traditional target and drug discovery process. | $334K / Seed / Nov 23, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Alderley Park Ventures invest in?
Alderley Park Ventures invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alderley Park Ventures last invest?
The most recent investment recorded for Alderley Park Ventures closed in Apr 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
